28 Mar 2022 12:17

The Lancet publishes article on proven efficacy of Sputnik V in protecting HIV-positive people from Covid-19 - RDIF

MOSCOW. March 28 (Interfax) - Sputnik V is the world's first vaccine with proven efficacy in protecting HIV-positive people from coronavirus; the efficacy of the vaccine for this category of people is 79%, the Russian Direct Investment Fund (RDIF) said.

"The Russian Health Ministry's Gamaleya Epidemiology and Microbiology Research Institute and the Russian Direct Investment Fund announce the publication in the leading medical magazine The Lancet of a scientific article confirming that Sputnik V is the world's first vaccine with proven efficacy in protecting HIV-positive people who are receiving antiretroviral therapy against coronavirus," RDIF said in a report released on Monday.

The efficacy of the coronavirus vaccine in HIV-positive citizens was proven by a joint study conducted by the Russian Health Ministry's Gamaleya Epidemiology and Microbiology Research Institute and the Moscow Center for HIV/AIDS Prevention and Treatment, published in the magazine The Lancet, the report said.

The report said, citing scientific data provided in the article, that the efficacy of the Russian Sputnik V coronavirus vaccine for this category of people reached 79%, according to the analysis of data of more than 24,000 HIV-positive patients in Moscow who are receiving antiretroviral therapy.

Sputnik V efficacy against hospitalization among HIV-positive people has exceeded 90%, while efficacy against moderate and grave Covid-19 cases topped 97%, the fund said.

"Sputnik V can become the best decision for protection of the health of HIV-positive people, including in countries with a considerable percentage of HIV-positive people, to whom coronavirus infection poses a high danger," the press service said.

RDIF said, citing data from the World Health Organization (WHO) published earlier, that more than 23% of the HIV-positive people hospitalized with coronavirus had died.